CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cellromax Science Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cellromax Science Co Ltd
357 Guseong-Ro, Giheung-Gu
Phone: +82 316621395p:+82 316621395 YONGIN, 16914  South Korea Ticker: 471820471820
Business Summary
Cellromax Science Co Ltd is a Korea-based company primarily engaged in the development and distribution of health food products. The Company primarily engages in the development and distribution of health functional foods, functional cosmetics, and general medicines. In addition, the Company’s brands include ‘Cellromax’ and so on.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023-----

Industries
SIC Code Description
2099 Food preparations, not elsewhere classified

General Information
Outstanding Shares: 11,644,079 (As of 12/13/2024)
Stock Exchange: KDQ
Fax Number: +82 312821395


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 22, 2024